Mar - Presented at BioTech NZ Life Science Summit in Wellington, NZ

Feb - ASX Startup Zone place winners

Dec - Presented poster at CBDS&T Conference in Florida, USA

Nov - Merck Emerging Biotech Grants ‘Special Mention’ winners

Oct - Closed NZ$14M Series A capital raise

Aug - Honoured in Fierce Biotech's 2024 'Fierce 15' - the best and brightest of biotech

May - Small scale in vivo study confirms safety and efficacy in living organisms

Feb - Announced positive test results against Dengue (all four serotypes) and HSV-2

Dec - Awarded NZ$1.3M DTRA funded contract for custom antiviral development

Aug - Freedom to Operate search complete, multiple patent investigations begun

Jul - Awarded Arohia Seed Grant from Callaghan Innovation

Jun - Announced 100% positive test results against Dengue (serotypes 1 and 2) and Zika viruses

Apr - Export Control and ITAR Approved by US State Department

Nov - Established our MPI-approved PC-2 (BSL-2) laboratory

Oct - Received NZ$220K donation

Jul - Awarded $150K R&D Grant from Callaghan Innovation

Mar - Discovered significant protein fabrication process improvements

Feb - Completed protein stability studies

Jan - Confirmed dsRNA binding (MOA)

Jul - Established our Nelson Office

Jun - Accepted into US National Institute of Health (NIH) Antiviral Testing Programme

May - First successful antiviral test results recorded against Dengue

Apr - Awarded Startup Grant from Callaghan Innovation

Mar - Closed Seed funding round with NZ$4.2M raised

Kimer Med was founded in August 2020

Progress